Hepatitis: Clinical Trials

614 trials for Hepatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

614 completed. 614 Phase 2, 67 Phase 1, 46 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2614Completed 614
Phase 167Completed 67
Phase 346Completed 46

Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis

Trials (filtered) newest first · largest first

All 614 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D
hepalatide - Hepatitis D
Phase 2CompletedShanghai HEP Pharmaceutical Co., Ltd.902024-12-112026-10-29
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
ADX-629 - Alcohol Hepatitis
Phase 2CompletedAldeyra Therapeutics, Inc.42024-11-042026-06-03
Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).
AHB-137 (24 weeks), AHB-137 and Placebo, AHB-137 (16 weeks) - Hepatitis B, Chronic
Phase 2CompletedAusper Biopharma Co., Ltd.862024-07-102026-09-15
A Study of RBD1016 in CHB Participants
RBD1016 - Chronic Hepatitis b
Phase 2CompletedSuzhou Ribo Life Science Co. Ltd.482023-10-112025-12-09
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
Hepalatide, Hepalatide Placebo - Chronic Hepatitis D Infection
Phase 2CompletedShanghai HEP Pharmaceutical Co., Ltd.232023-10-072024-04-24
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
PEG-IFNα, BRII-835 - Chronic Hepatitis B Virus Infection
Phase 2CompletedBrii Biosciences Limited862023-08-222026-10-20
A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients
AHB-137 injection, Placebo - Hepatitis B, Chronic
Phase 1 / Phase 2CompletedAusper Biopharma Co., Ltd.1292023-08-032026-05-07
A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
HRS9950 tablets, HRS9950 placebo tablets - Chronic Hepatitis B
Phase 2CompletedChengdu Suncadia Medicine Co., Ltd.542023-07-282024-12-03
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic
Phase 2CompletedAtea Pharmaceuticals, Inc.2752023-05-302025-10-21
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
zetomipzomib, placebo, zetomipzomib in open-label extension - Autoimmune Hepatitis
Phase 2CompletedKezar Life Sciences, Inc.242023-05-232026-01-13
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
VIR-3434, VIR-2218, TDF - Hepatitis B, Chronic
Phase 1 / Phase 2CompletedVir Biotechnology, Inc.332023-05-102026-02-09
Glecaprevir/Pibrentasvir for the Treatment of PTSD
Glecaprevir / Pibrentasvir Pill - PTSD
Phase 2 / Phase 3CompletedWhite River Junction Veterans Affairs Medical Center102023-04-012024-08-29
Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets
GST-HG141 - Chronic Hepatitis b
Phase 2CompletedFujian Akeylink Biotechnology Co., Ltd.902023-01-032025-03-05
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
HR19042 Capsules - Autoimmune Hepatitis
Phase 2CompletedJiangsu HengRui Medicine Co., Ltd.692022-10-062025-03-24
Efficacy of VTP-300 in Chronic Hepatitis B Infection
ChAdOx1-HBV, MVA-HBV, Nivolumab - Chronic Hepatitis B
Phase 2CompletedBarinthus Biotherapeutics1212022-09-212026-04-30
A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients
Hepalatide, Placebo of Hepalatide, Tenofovir Alafenamide Tablets - Chronic Hepatitis B
Phase 2CompletedShanghai HEP Pharmaceutical Co., Ltd.82022-08-232024-07-15
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil - Hepatitis B, Chronic
Phase 2CompletedJanssen Research & Development, LLC372022-06-302025-04-25
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
GSK3228836, GSK3528869A, Control - Hepatitis B, Chronic
Phase 2CompletedGlaxoSmithKline1742022-03-222025-12-30
Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV
ASC42 10mg, ASC42 15mg, ih PEG-IFN α-2a - Hepatitis B, Chronic
Phase 2CompletedAscletis Pharmaceuticals Co., Ltd.432022-01-102024-04-04
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone
MTL-CEBPA, Sorafenib - Hepatocellular Carcinoma, Hepatitis B
Phase 2CompletedMina Alpha Limited82022-01-012025-03-06

Showing 20 of 614. Sign in to see all of them.

Narrower conditions

Hepatitis C (267)  ·  Hepatitis C, Chronic (194)  ·  Hepatitis B (101)  ·  Hepatitis B, Chronic (94)  ·  HIV Infections (32)  ·  Fibrosis (23)  ·  Liver Diseases (21)  ·  Tetanus (19)  ·  Diphtheria (18)  ·  Haemophilus Infections (15)  ·  Hepatitis, Alcoholic (15)  ·  Poliomyelitis (14)  ·  Hepatitis, Chronic (11)  ·  Liver Cirrhosis (11)

Broader conditions

Digestive System Diseases (612)  ·  Liver Diseases (593)  ·  Infections (577)  ·  Hepatitis, Viral, Human (573)  ·  Virus Diseases (570)  ·  Blood-Borne Infections (557)  ·  Communicable Diseases (554)  ·  RNA Virus Infections (432)  ·  Flaviviridae Infections (388)  ·  Pathological Conditions, Signs and Symptoms (331)  ·  Pathologic Processes (329)  ·  Disease Attributes (304)  ·  Chronic Disease (302)  ·  Hepatitis, Chronic (298)

Interventions

Ribavirin (201)  ·  peginterferon alfa-2a (116)  ·  Sofosbuvir (49)  ·  entecavir (28)  ·  Ritonavir (27)  ·  peginterferon alfa-2b (27)  ·  daclatasvir (26)  ·  Tenofovir (25)  ·  ledipasvir, sofosbuvir drug combination (24)  ·  Simeprevir (19)  ·  grazoprevir (17)  ·  paritaprevir (17)  ·  sofosbuvir-velpatasvir drug combination (17)  ·  telaprevir (17)  ·  ombitasvir (15)

Sponsors

Gilead Sciences (70)  ·  Merck Sharp & Dohme LLC (36)  ·  GlaxoSmithKline (35)  ·  Bristol-Myers Squibb (31)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (22)  ·  Hoffmann-La Roche (21)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (17)  ·  AbbVie (14)  ·  Vertex Pharmaceuticals Incorporated (13)  ·  AbbVie (prior sponsor, Abbott) (11)  ·  ANRS, Emerging Infectious Diseases (10)  ·  Boehringer Ingelheim (9)  ·  Janssen Research & Development, LLC (8)  ·  French National Agency for Research on AIDS and Viral Hepatitis (7)  ·  Romark Laboratories L.C. (7)

Countries

United States (281)  ·  France (90)  ·  Germany (88)  ·  Canada (71)  ·  Puerto Rico (66)  ·  United Kingdom (64)  ·  New Zealand (55)  ·  China (51)  ·  Spain (51)  ·  Australia (45)  ·  Belgium (45)  ·  Italy (42)  ·  South Korea (40)  ·  Taiwan (38)  ·  Poland (34)

Top investigators

Robert H. Hyland, DPhil (5)  ·  Asem Elfert, MD (4)  ·  Daniel Cohen, MD (4)  ·  Marc G Ghany, M.D. (4)

Results publications

PMID 28193518, PMID 30012435, PMID 30664876, PMID 30923816, PMID 30977945, PMID 37011138, PMID 20657177, PMID 24154738, PMID 24209977, PMID 24983020, PMID 25164700, PMID 25445400, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 27257978, PMID 28340322, PMID 28412293, PMID 28802814, PMID 28802816, PMID 30850240, PMID 31568620, PMID 35179437, PMID 39950613, PMID 41042426, PMID 11605686, PMID 12620148, PMID 15282352, PMID 15316341, PMID 15374882, PMID 15563253, PMID 15667486, PMID 15685543, PMID 15763232, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 16544259, PMID 16871563, PMID 16987047, PMID 17058225, PMID 17058240, PMID 17109339, PMID 17147494, PMID 17200799, PMID 17263626, PMID 17329696

NIH funding

2014 (15), 2016 (11), 2009 (9), 2015 (9), 2019 (7), 2008 (4), 2017 (3), 2004 (2), 2023 (2), R01DA026727 (2), U01AA021886 (2), 2005 (1), 2018 (1), N01CN35160 (1), P01AI055793 (1)